+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Direct-acting Antiviral Drug Market by Product Type, Therapeutic Class, Molecule, Distribution Channel, End User, Indication, Patient Type - Global Forecast to 2030- Product Image
Direct-acting Antiviral Drug Market by Product Type, Therapeutic Class, Molecule, Distribution Channel, End User, Indication, Patient Type - Global Forecast to 2030- Product Image
Sale

Direct-acting Antiviral Drug Market by Product Type, Therapeutic Class, Molecule, Distribution Channel, End User, Indication, Patient Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5311192
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Direct-acting Antiviral Drug Market grew from USD 12.18 billion in 2024 to USD 13.87 billion in 2025. It is expected to continue growing at a CAGR of 13.31%, reaching USD 25.79 billion by 2030.

Navigating the Emergence of Direct-Acting Antiviral Therapies

Direct-acting antiviral therapies have redefined the standard of care for hepatitis C, ushering in an era of highly effective, short-duration regimens that achieve unprecedented cure rates. As the field moves beyond interferon-based approaches, these targeted agents disrupt viral replication at multiple stages, delivering significant clinical benefits while reducing adverse events. This transformation is underpinned by advances in molecular biology, streamlined clinical trial designs, and collaborative partnerships that span academic institutions, biotech innovators, and global pharmaceutical leaders.

With health systems striving to eliminate hepatitis C as a public health threat, stakeholders must navigate a complex matrix of pricing pressures, patient access programs, and evolving reimbursement frameworks. The rapid uptake of direct-acting antivirals reflects both the urgent unmet need and the promise of durable response, yet the market remains highly dynamic. Payers and providers are recalibrating treatment algorithms to balance cost containment with outcome-driven care, while manufacturers are optimizing portfolios through lifecycle management and next-generation combination therapies. As the therapeutic landscape continues to expand, a thorough understanding of market drivers, barriers, and emerging opportunities is essential for strategic decision making.

Pivotal Transformations Reshaping the Antiviral Landscape

The antiviral landscape has undergone pivotal transformations that extend far beyond incremental improvements in drug potency. Breakthroughs in combination regimens now permit pan-genotypic coverage and drastically shortened treatment durations, enabling providers to streamline therapy pathways. The integration of digital health solutions, including remote adherence monitoring and telehealth-enabled patient support, further enhances real-world effectiveness by addressing barriers to treatment initiation and completion.

Simultaneously, innovative pricing models such as outcome-based contracting and subscription payment frameworks are gaining traction, incentivizing value-driven care and fostering partnerships between manufacturers and health systems. Regulatory agencies have adopted accelerated review pathways and real-world evidence frameworks to expedite approval for therapies that demonstrate clear clinical benefit. Meanwhile, increased collaboration between large pharmaceutical companies and specialized biotech firms has catalyzed the creation of next-generation molecules targeting resistant viral strains. Together, these shifts underscore a market in flux, ripe with potential for stakeholders who can anticipate and adapt to new paradigms in research, development, and commercialization.

Anticipating the Effects of 2025 Tariff Changes on US Market Access

As the United States prepares to implement tariff adjustments in 2025, industry participants are evaluating the potential impact on manufacturing costs, supply chain resilience, and final dosing prices. Antiviral APIs sourced from international suppliers may face higher import duties, prompting companies to reassess sourcing strategies and consider near-shore or domestic production capabilities. Such shifts could introduce time-to-market delays for generic entrants and put upward pressure on pricing for both branded and unbranded formulations.

Consequently, manufacturers are engaging with contract development and manufacturing organizations to secure supply continuity and negotiating long-term agreements to mitigate volatility. Providers and payers are also monitoring rebate architectures, given that net pricing structures could fluctuate in response to tariff-driven cost increases. In this environment, strategic alignment across the value chain becomes critical; companies that proactively diversify their supplier base and invest in robust inventory buffers will be better positioned to navigate tariff-related disruptions and maintain stable access to life-saving therapies.

Unveiling Market Dynamics Through Strategic Segmentation

Understanding the direct-acting antiviral market requires a nuanced view of how each product category contributes to overall dynamics. Products classified as either branded or generic carry distinct pricing and reimbursement considerations, influencing uptake across public and private payers. Therapeutic classes span combination therapies that integrate multiple mechanisms of action alongside specialized agents such as NS5A inhibitors, NS5B inhibitors, and protease inhibitors, each addressing unique segments of the viral replication cycle. At the molecular level, landmark compounds like Daclatasvir, Elbasvir/Grazoprevir, Ledipasvir/Sofosbuvir, Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir, and Sofosbuvir/Velpatasvir define clinical pathways, with variations in safety, efficacy, and genotype coverage driving prescribing patterns. Distribution channels range from hospital pharmacies catering to inpatient and outpatient clinic needs to online platforms facilitating remote patient access and traditional retail pharmacies serving broad community networks. End users include home healthcare models that support self-administration, hospitals that deliver acute care services, and specialized clinics focused on viral hepatology. Indication segmentation between Hepatitis C Genotype 1 and Genotype 3 informs regimen selection based on regional epidemiology and payer preferences. Finally, the distinction between treatment-experienced and treatment-naive patient populations underscores differing responder profiles and guides label expansions for next-generation agents.

Regional Variations Driving Antiviral Adoption Globally

Regional patterns in direct-acting antiviral adoption reveal diverse drivers and constraints across major territories. In the Americas, robust healthcare infrastructure, high per capita treatment rates, and innovative coverage models have accelerated market penetration, while the presence of leading pharmaceutical research hubs fuels ongoing pipeline development. Europe, the Middle East and Africa present a heterogeneous landscape where national reimbursement policies, variable public health priorities, and emerging access initiatives shape therapy availability; cross-country harmonization efforts and centralized procurement agreements are emerging to streamline distribution. In Asia-Pacific, burgeoning patient populations and evolving regulatory frameworks have spurred rapid uptake of generic formulations alongside selective adoption of premium branded regimens; government-led elimination programs and tiered pricing strategies further influence market expansion. Collectively, these regional insights highlight the importance of tailored go-to-market strategies that address local epidemiology, payer environments, and supply chain capabilities.

Competitive Positioning and Strategic Priorities of Leading Players

Leading players have adopted differentiated approaches to maintain and grow their market share amid intensifying competition. Certain global pharmaceutical companies leverage extensive commercial networks and established payer relationships to drive adoption of high-value branded regimens, supplementing these efforts with patient assistance programs that reduce out-of-pocket costs. Specialty biotech firms focus on niche therapeutic classes and hard-to-treat genotypes, advancing next-generation molecules through targeted clinical collaborations and orphan drug pathways. Generic manufacturers employ agile production models and cost leadership strategies to capture price-sensitive segments, often negotiating supply agreements with large procurement entities. Strategic alliances, licensing deals, and patent settlements continue to reshape the competitive landscape, with merger and acquisition activity enabling rapid portfolio expansion and technology transfer. These collective efforts underscore a market characterized by dynamic partnerships, evolving IP landscapes, and relentless innovation in both established and emerging markets.

Strategic Imperatives for Industry Leaders

To thrive in this rapidly evolving market, industry leaders must embrace multifaceted strategies that balance innovation, cost efficiency, and patient access. Companies should prioritize diversification of their pipeline by advancing pan-genotypic therapies with improved safety profiles and shorter treatment durations. Strengthening supply chain resilience through dual sourcing agreements and regional manufacturing partnerships will mitigate the impact of trade policy shifts. Engaging payers with value-based contracting models and real-world evidence on long-term outcomes can unlock broader coverage and favorable formulary access. Digital patient support tools should be integrated into commercialization plans to boost adherence and monitor real-world effectiveness. In parallel, targeted expansion into underserved regions via tiered pricing and public-private partnerships can capture incremental volume and support global elimination goals. By aligning commercial, clinical, and operational initiatives, companies can secure sustainable growth and deliver transformative value to patients and healthcare systems alike.

Rigorous Methodology Underpinning Market Insights

This analysis is grounded in a robust methodology that synthesizes qualitative and quantitative research techniques. Primary research included in-depth interviews with key opinion leaders, payers, healthcare providers, and patient advocacy groups to validate clinical and commercial assumptions. Secondary research encompassed a thorough review of peer-reviewed journals, regulatory filings, trade publications, and corporate disclosures, ensuring comprehensive coverage of therapeutic advances and policy developments. Data triangulation methods were employed to reconcile discrepancies across sources and confirm the reliability of market drivers and barriers. Segmentation frameworks were applied to capture nuances across product types, therapeutic classes, molecules, distribution channels, end users, indications, and patient subgroups. Regional analyses incorporated epidemiological data, reimbursement landscapes, and competitive intelligence. All findings were subjected to expert panel review and methodological audits to guarantee accuracy, relevance, and transparency.

Consolidating Insights for Informed Decision Making

Direct-acting antiviral drugs have transformed hepatitis C treatment, offering curative outcomes and redefining therapeutic standards. The confluence of novel molecules, patient-centric delivery models, and innovative contracting frameworks underscores a market of sustained momentum and strategic complexity. As tariff changes loom, supply chain agility and proactive sourcing will differentiate resilient players, while segmentation and regional variations demand tailored commercial strategies. Leading companies are forging alliances, optimizing pipelines, and deploying digital solutions to stay ahead in a competitive landscape. For stakeholders across the value chain, the insights presented here provide a blueprint for navigating regulatory shifts, capitalizing on emerging opportunities, and delivering life-saving therapies to patients worldwide. The path forward will favor those who couple scientific innovation with strategic foresight and operational excellence.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Branded Drugs
    • Generic Drugs
  • Therapeutic Class
    • Combination Therapy
    • Ns5A Inhibitor
    • Ns5B Inhibitor
    • Protease Inhibitor
  • Molecule
    • Daclatasvir
    • Elbasvir/Grazoprevir
    • Ledipasvir/Sofosbuvir
    • Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir
    • Sofosbuvir/Velpatasvir
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Home Healthcare
    • Hospitals
    • Specialty Clinics
  • Indication
    • Hepatitis C Genotype 1
    • Hepatitis C Genotype 3
  • Patient Type
    • Treatment-Experienced
    • Treatment-Naive
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Janssen Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Cipla Limited
  • Aurobindo Pharma Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Direct-acting Antiviral Drug Market, by Product Type
8.1. Introduction
8.2. Branded Drugs
8.3. Generic Drugs
9. Direct-acting Antiviral Drug Market, by Therapeutic Class
9.1. Introduction
9.2. Combination Therapy
9.3. Ns5A Inhibitor
9.4. Ns5B Inhibitor
9.5. Protease Inhibitor
10. Direct-acting Antiviral Drug Market, by Molecule
10.1. Introduction
10.2. Daclatasvir
10.3. Elbasvir/Grazoprevir
10.4. Ledipasvir/Sofosbuvir
10.5. Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir
10.6. Sofosbuvir/Velpatasvir
11. Direct-acting Antiviral Drug Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Direct-acting Antiviral Drug Market, by End User
12.1. Introduction
12.2. Home Healthcare
12.3. Hospitals
12.4. Specialty Clinics
13. Direct-acting Antiviral Drug Market, by Indication
13.1. Introduction
13.2. Hepatitis C Genotype 1
13.3. Hepatitis C Genotype 3
14. Direct-acting Antiviral Drug Market, by Patient Type
14.1. Introduction
14.2. Treatment-Experienced
14.3. Treatment-Naive
15. Americas Direct-acting Antiviral Drug Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Direct-acting Antiviral Drug Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Direct-acting Antiviral Drug Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Gilead Sciences, Inc.
18.3.2. AbbVie Inc.
18.3.3. Merck & Co., Inc.
18.3.4. Janssen Pharmaceuticals, Inc.
18.3.5. Bristol-Myers Squibb Company
18.3.6. Roche Holding AG
18.3.7. Teva Pharmaceutical Industries Ltd.
18.3.8. Mylan N.V.
18.3.9. Cipla Limited
18.3.10. Aurobindo Pharma Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET MULTI-CURRENCY
FIGURE 2. DIRECT-ACTING ANTIVIRAL DRUG MARKET MULTI-LANGUAGE
FIGURE 3. DIRECT-ACTING ANTIVIRAL DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DACLATASVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ELBASVIR/GRAZOPREVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY LEDIPASVIR/SOFOSBUVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PARITAPREVIR/RITONAVIR/OMBITASVIR/DASABUVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SOFOSBUVIR/VELPATASVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C GENOTYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C GENOTYPE 3, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT-EXPERIENCED, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TREATMENT-NAIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 52. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 53. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 102. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 103. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 116. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 117. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 123. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 124. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 151. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 152. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 165. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 166. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 172. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 173. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 191. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 193. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 194. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 200. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 201. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 214. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 215. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 221. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 222. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 241. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 243. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 244. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 247. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 250. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 251. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 257. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 258. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 285. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 286. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 289. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 312. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 313. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM DIRECT-ACTI

Companies Mentioned

The companies profiled in this Direct-acting Antiviral Drug market report include:
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Janssen Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Cipla Limited
  • Aurobindo Pharma Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 13.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 25.79 Billion
Compound Annual Growth Rate13.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 181 Pages
  • Global
From
Antiviral Drugs Market by Indication, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Antiviral Drugs Market by Indication, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Antiviral Therapeutics Market by Disease Type, Drug Class, Route Of Administration, Distribution Channel, Therapy Type - Global Forecast to 2030 - Product Image

Antiviral Therapeutics Market by Disease Type, Drug Class, Route Of Administration, Distribution Channel, Therapy Type - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By Country: 2020-2030 - Product Image

Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By Country: 2020-2030

  • Report
  • 296 Pages
  • Global
From

About the Direct Acting Antiviral Drug Market

Direct-acting antiviral drugs (DAAs) represent a class of pharmaceuticals specifically targeting viruses at the molecular level to prevent their proliferation. Within the broader category of infectious diseases drugs, DAAs are used mainly for the treatment of viral infections such as hepatitis C and can have a transformative effect by providing high cure rates and shortened treatment durations compared to older interferon-based therapies. These drugs act directly on viral enzymes and proteins critical to the viral life cycle, disrupting processes such as viral RNA replication and protein production. Their development has been a major advance in the therapeutic management of chronic viral infections, leading to substantial improvements in patient outcomes. The DAA market is characterized by innovation and rapid development of new therapies that offer improved efficacy and safety profiles. Key players in the direct-acting antiviral drug market include Gilead Sciences, Merck & Co., AbbVie Inc., and Bristol-Myers Squibb. Gilead Sciences, for example, is known for its portfolio of DAAs for the treatment of hepatitis C, which has redefined the standard of care in this therapeutic area. These companies are continuously engaged in the research and development of new DAAs that promise to enhance patient care and expand therapeutic options for various viral infections. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.